Effective immediately, Sudhakar Akul Yakkanti, MSc, MPhill & PhD, resigned his position as Editor-in-Chief of Journal of Cancer Science and Therapy (JCST) and as member of other positions held at OMICS Group journals and conferences to pursue a new direction closer to his heart. During his tenure with OMICS Group, Dr. Yakkanti has contributed to the group’s extremely successful efforts in obtaining world-class editorials and the development of successful Cancer Conferences for four consecutive years. Dr. Yakkanti is appreciative of the time he spent with OMICS Group journals and wishes the editorial board colleagues in the respective fields he was associated with only the best.
Dr. Yakkanti is a renowned Cell Signaling scientist specializing in tumor angiogenesis and one of the world’s leading authorities on the subject of Type IV collagen derived metabolites. His co-discovery with Dr. Yohei Maeshima of the ‘alpha3 type IV collagen NC1 domain (Tumstatin) sometimes referred to as the ‘alport gene’ also an anticancer gene -made CNN headlines. The article: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis, published in Science [295(5552), 140-143, 2002] changed the view on how endogenous angiogenesis inhibitors inhibit tumor angiogenesis. Dr. Yakkanti is a former Associate Director and Senior Scientist, Center for Cancer & Metabolism, at the Stanford Research Institute (SRI) International, Menlo Park, California.
In the near future, Dr. Yakkanti will be focusing his efforts on what he considers to be one of his most consequential endeavors to date as a scientist – the role of extracellular matrix Type IV collagen derived metabolites and their interactions with cells in tumor angiogenesis and metastasis. He is also planning to be involved in the development of Scientific Journals and Conferences covering untapped areas of science and technology with emphasis on scientific ethics and policies.
Sudhakar Akul Yakkanti received his MSc, MPhil & PhD in Biochemistry from Department of Biochemistry and School of Life Sciences, University of Hyderabad. He did his postdoctoral training at Harvard Medical School, Boston, MA. He has published more than 60 abstracts; about 46 peer-reviewed research articles reviews in high impact journals (including Science, Journal of Clinical Investigation, Cancer Cell, Blood, PNAS etc.). Dr. Yakkanti has been the recipient of NIH grant and the prestigious Flight Attendant Medical Research Institute (FAMRI) Young Clinical Scientist award Grants twice. He received many awards and fellowships including Indian President’s fellowships, Graduate Aptitude Test of Engineering Fellowship, Council of Scientific Industrial Research Junior and Senior Research Fellowships, FAMRI Young Clinical Scientist Award, Bioequivalence & Bioavailability Young Scientist Award and Michael A. O’Connor Young Investigator Award. His research focuses on Extra Cellular matrix Type IV collagens derived metabolites interactions with cells and regulate tumor angiogenesis and metastasis. Dr. Yakkanti served as grant reviewer for NIH/NCI-DT study sections, NCI/NIH-Oncology-2 Translational Clinical IRG (OTC) study section and American Institute of Biological Sciences study section. He served as an Editor-in-Chief and member of Editorial board of many journals and also honored as keynote speaker and session chair for many national and international conferences.
Distributed by HeadlinePlus Press Release Distribution
Company Name: Omni Publicity
Contact Person: Joe Ullrich
City: San Francisco
Country: United States